Helix BioPharma Corp. (OTCMKTS:HBPCF – Get Free Report)’s share price shot up 20.7% during mid-day trading on Tuesday . The stock traded as high as $0.17 and last traded at $0.17. 1,000 shares were traded during trading, The stock had previously closed at $0.14.
Helix BioPharma Price Performance
The company’s fifty day moving average is $0.14 and its 200-day moving average is $0.14. The stock has a market cap of $40.74 million, a PE ratio of -8.31 and a beta of 0.01.
Helix BioPharma Company Profile
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging.
Read More
- Five stocks we like better than Helix BioPharma
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Sales Breakout Sends This Semiconductor Stock to Record High
- Are Penny Stocks a Good Fit for Your Portfolio?
- Surprise Buying Opportunity on This Dividend Aristocrat
- Golden Cross Stocks: Pattern, Examples and Charts
- New Theme Park Powerhouse: Merger Creates Industry-Leading Stock
Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
